New Study: Blood Test Shows Promise for Detecting Pancreatic Cancer at Its Earliest Stages
PANXEON, which combines multiple biomarkers, also identified a precancerous condition of the pancreas, potentially opening a path to intervention before invasive cancer develops
This page is Both News's AI analysis of the article, not the article itself. Read the full story on the publisher's site.
Read the original articleCity of Hope · cityofhope.orgOur verdict
Political lean
0 = center. The further from 0, the stronger the lean (max 10).
Reporting balance
How complete and even-handed the reporting is — separate from which side it leans.
This is an institutional press release about a City of Hope blood test; it has no left-right political lean but a clear promotional tone, with only the developers quoted and evaluative phrases such as 'very encouraging' and 'potentially curable' running ahead of the data. The most important strength is that the false-positive rates are given separately for low- and high-risk groups; the main weakness is the lack of any independent expert view and the conflict-of-interest disclosure sitting in a footnote. Readers should look for independent commentary and the full Nature Medicine paper before treating the test as a clinical advance.
- Why this lean
- The story has no left-right political angle; it concerns a medical test. The score stays at 0 because nothing in the framing, sourcing or wording favours a political side. The more important slant is institutional and commercial promotion, which is covered in the dimensions and findings.
- Framing
- Told from the developers' point of view: the central question is how much earlier PANXEON can detect pancreatic cancer, and the story answers that the test is promising.
Confidence: Medium — The supplied text is a full press release with no headline and no independent reporting, so the assessment reflects the institutional framing; the study itself was not checked. Medical efficacy claims are beyond what this analysis can verify.
Key Findings
- 1Every quoted voice is a member of the developing team (only Dr. Goel is quoted by name), and the study is described through its own institution, so it has no independent assessment.
- 2The article presents PANXEON as 'investigational' but uses language of clinical benefit: 'could detect the disease much earlier... potentially curable' and 'has the potential to dramatically change when pancreatic cancer is detected and treated.'
- 3The disclosed false-positive rates are a strength: the article gives 3% for low-risk and 16% for high-risk groups instead of one reassuring number. But it does not explain what a 16% rate means for patient numbers, follow-up testing or cost.
- 4The conflict of interest is disclosed only in a footnote at the bottom, where Dr. Goel is described as a paid consultant to Biocartis, which holds an option on the rights. The claims it bears on (the 'first investigational test' and 'what sets PANXEON apart') appear earlier in the text, without the disclosure beside them.
- 5The article says the study tested 'previously reported promising results' in 'diverse clinical settings', but it does not say whether the samples were prospective or retrospective, or report the number of cases in each group.
- 6The statement that PANXEON 'is the first investigational test to combine these three biomarkers' is a self-claim with no independent check in the text.
Who gets a voice
- Ajay Goel, Ph.D., AGAFSenior author and chair of Molecular Diagnostics at City of Hope; also a paid consultant to Biocartis (disclosed at the end)Developer of the testMain voice
- City of Hope researchersAuthors of the Nature Medicine study; not individually quotedDeveloper teamMinor voice
- BiocartisCompany holding an option to acquire PANXEON rights; named only in the disclosureCommercial interestMinor voice
Loaded language
Evaluative praise from the developer replaces the data, so the reader is told how to feel about results before seeing them in full.
Predicts a large clinical effect that the investigational, unvalidated test has not yet shown.
The 'curable' framing presents a hoped-for outcome as an expected benefit.
Self-description by the institution, presented as a fact and not attributed.
Vivid metaphor that makes the test sound more informative than the evidence in the text shows.
Dimension Breakdown
Every quoted voice is one of the test's developers at City of Hope; no independent researchers, clinicians, or patient voices appear, so the study is described only by its own team.
Promotional adjectives run through the text ('Results were very encouraging', 'could dramatically change', 'a national leader'), and the lede's 'potentially curable' adds hope beyond what the data shows.
Several numbers are given with some context, including the split false-positive rates (3% vs 16%) and the sensitivity limits to stages 1-2, which is useful. Still missing are sample sizes per group, the study's comparators, and a clear statement of how the test performs against current approaches.
Only the developing team is heard, with no outside expert assessment of how the 16% false-positive rate or the lack of screening validation should be weighed.
The URL-style title ('shows promise') is a reasonable reading, but the body moves toward 'very encouraging' and 'potentially curable' claims that go beyond an investigational test's evidence.
Survival statistics are given, but there is no discussion of cost, clinical pathway, whether results were prospective, or how many cases would be flagged in practice, all of which a reader needs to judge the test.
Missing Perspectives
- Independent pancreatic cancer researchers or clinicians, who could say how the 16% false-positive rate and the 87% sensitivity compare with existing tests and imaging.
- Patients or patient advocates, who would address whether extra follow-up testing for high-risk patients is practical and what harm false positives can cause.
- Biocartis or any non-commercial source on the rights arrangement, and how it might affect the future availability and pricing of the test.
- Information on cost, insurance coverage and who would pay for PANXEON, which matters because the article itself says current surveillance is 'expensive'.
- The limits set out in the study, such as whether results need independent prospective validation before any clinical or screening use.
Highlighted Passages
“Results were very encouraging.”
“PANXEON takes a novel approach to testing and has the potential to dramatically change when pancreatic cancer is detected and treated.”
“It is the first investigational test to combine these three biomarkers into a single test.”
“is what sets PANXEON apart, Dr. Goel said.”
Key Facts
- According to City of Hope, the PANXEON liquid biopsy combines circulating microRNAs, exosomal microRNAs and CA19-9 into a single AI-derived risk score.
- According to the study, as reported by Dr. Goel's team, PANXEON correctly identified stage 1 and 2 pancreatic cancer 87% of the time.
- The study reports a false-positive rate of 3% in low-risk groups and 16% in high-risk groups.
- The study reports that PANXEON detected high-grade dysplasia more than 64% of the time.
- The study tested nearly 1,800 patients across the United States, Europe and Asia and was published in Nature Medicine.
- The article cites SEER data that 14% of pancreatic cancer patients are alive five years after diagnosis, and a published study that about 90% of tumors are detected at advanced stages.
- Dr. Goel is a paid consultant to Biocartis, which has an option to acquire rights to PANXEON.